Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Clin Ther. 2010 Aug;32(9):1597-609. doi: 10.1016/j.clinthera.2010.07.021.
Clin Ther. 2010.
PMID: 20974317